By Fineline Cube Yangtze River Pharmaceutical Group (YRPG) announced that China’s National Medical Products Administration (NMPA) has granted marketing approval for fazamorexant, a Category 1 innovative dual orexin receptor antagonist (DORA) indicated for the treatment of adult insomnia characterized by difficulty falling asleep and/or maintaining sleep.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Full marketing approval, Category 1 innovative drug |
| Product | Fazamorexant (oral) |
| Indication | Treatment of adult patients with insomnia (sleep onset and/or maintenance difficulties) |
| Approval Date | 22 May 2026 |
| Next Steps | Commercial launch preparation and market access negotiations |
Drug Profile & Mechanism of Action
- Molecule: Dual orexin receptor antagonist (DORA)
- Target: Orexin receptors OX1 and OX2 in the brain’s wake-promoting system
- Innovation: Demonstrates rapid onset of action with sustained efficacy over long-term use
- Intellectual Property: Developed by YRPG with proprietary formulation and clinical data package
Clinical Evidence – Phase III Trials
| Endpoint | Result (Fazamorexant) | Comparator (Other DORAs) | Relative Benefit |
|---|---|---|---|
| Time to Sleep Onset | Significantly reduced | Published clinical data | Numerically superior |
| Nighttime Awakenings | Markedly improved | Published clinical data | Numerically superior |
| Sleep Efficiency | Enhanced metrics | Published clinical data | Numerically superior |
| Long-term Efficacy | Benefits maintained at 6 months | Limited long-term data available | Sustained therapeutic effect |
| Safety | Discontinuation rate: 0.6%; No rebound insomnia or withdrawal symptoms | Variable across class | Favorable safety profile |
The pivotal Phase III studies demonstrated significant improvements in both objective sleep parameters measured by polysomnography (PSG) and subjective sleep indicators recorded in patient sleep diaries after just 14 days of treatment.
Market Impact & Outlook
- China Insomnia Landscape: Affecting approximately 15% of China’s adult population, representing a substantial market opportunity for effective, well-tolerated treatments
- Competitive Edge: Fazamorexant’s combination of rapid onset, sustained efficacy, and favorable safety profile differentiates it from existing insomnia therapies
- Commercial Strategy: YRPG plans to leverage its established distribution network to ensure broad market access across urban and rural healthcare settings
- Global Potential: The robust clinical data package may support future regulatory submissions in international markets seeking next-generation insomnia treatments
Forward‑Looking Statements
This brief contains forward-looking statements regarding commercial expectations for fazamorexant. Actual results may differ due to risks including market adoption, competitive dynamics, and reimbursement decisions.-Fineline Info & Tech